Suppr超能文献

通过协同Toll样受体配体增强编码树突状细胞靶向抗原的DNA疫苗的启动效力。

Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.

作者信息

Grossmann Claudius, Tenbusch Matthias, Nchinda Godwin, Temchura Vladimir, Nabi Ghulam, Stone Geoffrey W, Kornbluth Richard S, Uberla Klaus

机构信息

Department of Molecular and Medical Virology, Ruhr-Universität Bochum, Universitätsstrasse 150, 44801 Bochum, Germany.

出版信息

BMC Immunol. 2009 Aug 3;10:43. doi: 10.1186/1471-2172-10-43.

Abstract

BACKGROUND

Targeting of protein antigens to dendritic cells (DC) via the DEC205 receptor enhances presentation of antigen-derived peptides on MHC-I and MHC-II molecules and, in the presence of costimulatory signals, antigen-specific immune responses. The immunogenicity and efficacy of DNA vaccination can also be enhanced by fusing the encoded antigen to single chain antibodies directed against DEC205. To further improve this strategy, we evaluated different toll-like receptor ligands (TLR) and CD40 ligands (CD40L) as adjuvants for DNA vaccines encoding a DEC205-single-chain antibody fused to the ovalbumin model antigen or HIV-1 Gag and assessed the priming efficacy of DNA in a DNA prime adenoviral vector boost immunization regimen.

RESULTS

Mice were primed with the adjuvanted DEC-205 targeted DNA vaccines and boosted with adenoviral vectors encoding the same antigens. CD8+ T cell responses were determined after the adenoviral booster immunization, to determine how well the different DNA immunization regimens prime for the adenoviral boost. In the absence of adjuvants, targeting of DNA-encoded ovalbumin to DCs suppressed CD8+ T-cell responses after the adenoviral booster immunization. CD8+ T-cell responses to the DEC205 targeted DNA vaccines increased only slightly by adding either the TLR-9 ligand CpG, the TLR-3 ligand Poly I:C, or CD40 ligand expression plasmids. However, the combination of both TLR-ligands led to a strong enhancement of CD8+ T-cell responses compared to a non-targeted DNA vaccine. This finding was confirmed using HIV Gag as antigen.

CONCLUSION

Although DNA prime adenoviral vector boost immunizations belong to the strongest inducers of cytotoxic T cell responses in different animal models and humans, the CD8+ T cell responses can be further improved by targeting the DNA encoded antigen to DEC205 in the presence of synergistic TLR ligands CpG and Poly I:C.

摘要

背景

通过DEC205受体将蛋白质抗原靶向树突状细胞(DC)可增强抗原衍生肽在MHC-I和MHC-II分子上的呈递,并且在共刺激信号存在的情况下,可增强抗原特异性免疫反应。通过将编码抗原与针对DEC205的单链抗体融合,也可以增强DNA疫苗的免疫原性和效力。为了进一步改进该策略,我们评估了不同的 Toll 样受体配体(TLR)和CD40配体(CD40L)作为编码与卵清蛋白模型抗原或HIV-1 Gag融合的DEC205-单链抗体的DNA疫苗的佐剂,并在DNA初免腺病毒载体加强免疫方案中评估了DNA的启动效力。

结果

用佐剂化的DEC-205靶向DNA疫苗对小鼠进行初免,并用编码相同抗原的腺病毒载体进行加强免疫。在腺病毒加强免疫后测定CD8 + T细胞反应,以确定不同DNA免疫方案对腺病毒加强免疫的启动效果如何。在没有佐剂的情况下,将DNA编码的卵清蛋白靶向DC会抑制腺病毒加强免疫后的CD8 + T细胞反应。通过添加TLR-�配体CpG、TLR-3配体Poly I:C或CD40配体表达质粒,对DEC205靶向DNA疫苗的CD8 + T细胞反应仅略有增加。然而,与非靶向DNA疫苗相比,两种TLR配体的组合导致CD8 + T细胞反应的强烈增强。使用HIV Gag作为抗原证实了这一发现。

结论

尽管DNA初免腺病毒载体加强免疫在不同动物模型和人类中属于细胞毒性T细胞反应的最强诱导剂,但在协同TLR配体CpG和Poly I:C存在的情况下,通过将DNA编码抗原靶向DEC205,可以进一步改善CD8 + T细胞反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/137f/2731061/9475f6bca8e1/1471-2172-10-43-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验